You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Technology appraisal guidance
Reference number: TA243
Published: 25 January 2012

Guidance
Tools and resources
Information for the public
History

Appendix A: matrix of stakeholders

Appendix A: matrix of stakeholders

Appendix A: matrix of stakeholders
16 June 2014
(99.12 Kb 28 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 13 June 2014